LOS ANGELES, July 27, 2020 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), today announced that an investigator initiated study, authored by Dr. Samir Awad, Professor of Surgery at Baylor College of Medicine, entitled ‘The Impact of Pulsed Electromagnetic Field (SofPulse®) on Postoperative Pain in Patients Undergoing Cardiothoracic Surgery’ was accepted for oral presentation at the 44th Annual meeting of the Association of VA Surgeons.
The study was conducted on 31 patients from 1/1/2019 thru 12/31/2019 with sixteen patients using SofPulse® adjunctively for recovery and fifteen patients not using SofPulse®. Both groups of patients were well matched with no significant difference in: Age, BMI, Gender, Comorbidities, ETOH, Tobacco, and history of opioid use. The results of the study demonstrate that the use of SofPulse® significantly decreased postoperative pain VAS (Visual Analog Scale) by 50%, decreased postoperative opioid requirements (morphine equivalent dose) by 70%, and resulted in a significant decrease in Length of Stay at the hospital by a median of 2 days.
Endonovo CEO Alan Collier stated, “The economic findings, cost savings, and reduction of opioid use to hospitals and patients recovering from open heart types of surgeries from the Baylor College of Medicine study are stunning. Findings show a significant reduction in the median Length of Stay (LOS) of 2 days for open heart type of surgeries, we believe this makes SofPulse® a viable option for reducing length of stay on any inpatient or outpatient surgical procedure done in the US. Using SofPulse® for postoperative pain and edema reduction basically offers hospitals a cost savings from a reduction of the length of stay by 2 days for patients to recover from these types of surgeries. With hospital costs constantly going up and with a current per daily average of $3000 to $6000 for surgical recovery stays, this reduction in length of stay could equate to a $6,000 to $12,000 savings to hospitals, per patient, when using SofPulse® for these types of surgeries.”
Collier continues, “We are thrilled to announce that Dr. Awad will be presenting his research findings to his colleagues, the medical community and anyone in the public who would be interested. This independent study confirms the significant outcomes we continue to see in patients using SofPulse® for other similar types of painful surgeries like Urology and Orthopedics. Our company mission is to make SofPulse® available to any patient having surgery to help them reduce opioid use, decrease their recovery time, and improve recovery and outcomes from the surgical procedure. As hospitals around the country continue to add SofPulse® for management of post-operative pain and edema, the adoption and use of this effective Electroceutical® therapeutic technology continues to increase and build a market for SofPulse®. Additionally, many surgeons currently using SofPulse® are saying that “SofPulse® should be considered the standard of care in postoperative pain management of surgical patients to decrease opioid requirement and speed up the recovery process.”
Dr. Awad will presenting results of ‘The Impact of Pulsed Electromagnetic Field (SofPulse®) on Postoperative Pain in Patients Undergoing Cardiothoracic Surgery’ in a webinar presentation. Parties interested can schedule an appointment to attend via email at email@example.com.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of noninvasive wearable Electroceuticals® therapeutic devices. The Company’s current portfolio of commercial and clinical-stage wearable Electroceuticals® therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company’s noninvasive Electroceutical® therapeutic device, SofPulse®, which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema and has CMS national coverage for the treatment of chronic wounds. The Company’s current portfolio of preclinical-stage Electroceuticals® therapeutic devices addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company’s noninvasive, wearable Electroceuticals® therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur www.endonovo.com.
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company’s reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company’s estimates as of the date of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact:
Source: Endonovo Therapeutics Inc.